Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Resectable NSCLC

Interventions

DRUG

Tislelizumab

200mg, iv, Q3W, 3-4 cycle

RADIATION

3D-CRT/IMRT

40Gy in 20 fractions

Trial Locations (1)

RECRUITING

Jiangsu Northern People Hospital, Yangzhou

All Listed Sponsors

lead

Northern Jiangsu People's Hospital

OTHER

NCT07050056 - Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC | Biotech Hunter | Biotech Hunter